ankylosing spondylitis
Rheumatology · 2006–2025
34decisions
11medicines
12carried consumer input
8individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| etanercept Severe psoriatic arthritis, ankylosing spondylitis, severe active rheumatoid arthritis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2025 | Recommended with restriction | none received |
| infliximab Multiple indications including rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults and children (6 to 17 years), refractory Crohn's disease,… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing… | Mar 2025 | Recommended with restriction | input received |
| infliximab Amendment to restriction level for continuing treatment of severe active rheumatoid arthritis, severe Crohn disease, severe chronic plaque psoriasis, severe… | Mar 2025 | Recommended with restriction | input received |
| bimekizumab Treatment of radiographically confirmed (active) ankylosing spondylitis (AS) in adults who have failed to achieve adequate response following treatment with at… | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia |
| tofacitinib Treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy, specifically those who have failed to… | Mar 2023 | Recommended | 1 individuals Musculoskeletal Australia |
| infliximab Treatment of ankylosing spondylitis, severe chronic plaque psoriasis, severe active psoriatic arthritis, and complex refractory fistulising Crohn's disease via… | Mar 2022 | Recommended with restriction | unclear |
| adalimumab Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, chronic plaque psoriasis, ulcerative colitis, Crohn's disease, and… | Nov 2022 | Not recommended | 1 individuals |
| etanercept Listing of etanercept injection 50 mg in 1 mL single use dose-dispenser cartridges for the same indications as currently listed etanercept pre-filled syringes:… | Jul 2021 | Recommended with restriction | unclear |
| secukinumab Requested amendment to increase maximum quantity from one to two injections and reduce repeats from five to two for the continuing treatment phase of… | Jul 2021 | Not recommended | none received |
| upadacitinib Treatment of adults with ankylosing spondylitis following inadequate response to at least two non-steroidal anti-inflammatory drugs (NSAIDs) combined with an… | Mar 2021 | Recommended with restriction | none received |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile idiopathic arthritis. | Nov 2021 | Recommended | unclear |
| ixekizumab Treatment of adult patients with active ankylosing spondylitis (AS), radiographically confirmed. | Jul 2020 | Recommended | input received |
| etanercept Support for uptake of etanercept biosimilar (Brenzys) in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic plaque… | Dec 2020 | Not recommended | no section in document |
| infliximab Treatment of adults with severe active rheumatoid arthritis, ankylosing spondylitis, severe refractory Crohn's disease, complex refractory fistulising Crohn's… | Nov 2020 | Recommended with restriction | input received Colitis Australia · Parallel- Group |
| infliximab Subsequent continuing treatment for severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe Crohn disease, moderate to severe… | Mar 2019 | Recommended with restriction | 3 individuals |
| adalimumab Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile idiopathic arthritis, severe… | Jul 2018 | Recommended | 1 individuals |
| etanercept Biosimilar etanercept for multiple indications including severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic… | Mar 2018 | Recommended with restriction | none received |
| etanercept Proposed changes to the listing of etanercept (Brenzys brand) to support biosimilar uptake, including changes to authority requirements and treatment cycle… | Nov 2018 | Deferred | none received |
| etanercept severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, and severe chronic plaque psoriasis | Aug 2017 | Recommended with restriction | no section in document |
| certolizumab pegol Treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, and active ankylosing spondylitis. | Mar 2017 | Recommended with restriction | none received |
| infliximab Change to initial and continuing treatment restrictions for the biosimilar brand of infliximab (Renflexis) for severe active rheumatoid arthritis, ankylosing… | Nov 2017 | Recommended with restriction | none received |
| etanercept Biosimilar to etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended | input received |
| certolizumab pegol Loading dose administration (weeks 0, 2, and 4) for patients with ankylosing spondylitis, severe psoriatic arthritis, and severe active rheumatoid arthritis. | Mar 2016 | Recommended with restriction | no section in document |
| secukinumab Treatment of ankylosing spondylitis in TNFα-naive and TNFα-experienced patients. | Mar 2016 | Recommended with restriction | none received |
| infliximab Biosimilar to Remicade for multiple indications including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and… | Nov 2016 | Recommended | none received |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| certolizumab pegol Treatment of adults with active ankylosing spondylitis (AS) who have been intolerant to or have had inadequate response to at least one nonsteroidal… | Mar 2014 | Recommended with restriction | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at increased risk of… | Jul 2013 | Not recommended | no section in document |
| Naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in a patient who requires a non-steroidal anti-inflammatory drug… | Mar 2012 | Not recommended | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of… | Mar 2012 | Not recommended | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of… | Nov 2012 | Not recommended | unclear |
| golimumab treatment of adult patients with active ankylosing spondylitis (AS) | Mar 2010 | Recommended with restriction | no section in document |
| adalimumab treating adults with ankylosing spondylitis who have had an inadequate response to conventional therapy | Nov 2006 | Recommended with restriction | no section in document |
Who spoke
Colitis Australia · CreakyJoints Australia · Parallel- Group · Musculoskeletal Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 12 of 28 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.